The natural alkaloid 20-(S)-Camptothecin (CPT) is derived from the bark of the Camptotheca acuminata tree (Chinese happy tree). It works as a DNA topoisomerase 1 toxin with intriguing anticancer properties, but its application is restricted due to low stability and unexpected drug-drug interactions. It has been widely employed in cancer therapy since the late twentieth century, and because extraction yields from plant tissues are limited, multiple synthetic approaches have been devised to meet the increased demand for CPT. SAR investigations have also aided the creation of more potent CPT analogues, such as topotecan and irinotecan. Sadly, resistance has already developed in a number of tumour lines. More research is needed to better understand the relationship between substituents and resistance, as well as the clinical implications of relevant gene polymorphisms. Modifying the delivery mechanism to promote tumour cell absorption and reduce toxicity is one of the most recent study efforts [1].
Author (S) Details
Seema Manchanda
B. K. Birla College, Kalyan, Maharashtra, India.
View Book :- https://stm.bookpi.org/NICB-V1/article/view/3349
No comments:
Post a Comment